Click here to get full coverage on Galmed Issues CEO Letter to Shareholders - PR Newswire

Galmed Issues CEO Letter to Shareholders  PR Newswire

Galmed Issues CEO Letter to Shareholders - PR Newswire

Click here to get full coverage on Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement - Stock Titan

Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement  Stock Titan

Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement - Stock Titan

Click here to get full coverage on Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update  PR Newswire

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on Galmed Pharmaceuticals: Is It A Turnaround Story? - timothysykes.com

Galmed Pharmaceuticals: Is It A Turnaround Story?  timothysykes.com

Galmed Pharmaceuticals: Is It A Turnaround Story? - timothysykes.com

Click here to get full coverage on Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com

Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook  Investing.com

Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com

Click here to get full coverage on Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study - TipRanks

Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study  TipRanks

Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study - TipRanks

Click here to get full coverage on Galmed (NASDAQ: GLMD) 3-Drug Combo Shows Synergy in GI Tumor Models Study Results - Stock Titan

Galmed (NASDAQ: GLMD) 3-Drug Combo Shows Synergy in GI Tumor Models Study Results  Stock Titan

Galmed (NASDAQ: GLMD) 3-Drug Combo Shows Synergy in GI Tumor Models Study Results - Stock Titan

Click here to get full coverage on Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks - Stocktwits

Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks  Stocktwits

Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks - Stocktwits

Click here to get full coverage on Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update  PR Newswire

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update  PR Newswire

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - PR Newswire

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH  PR Newswire

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - PR Newswire

Click here to get full coverage on Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PR Newswire

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting  PR Newswire

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PR Newswire

Click here to get full coverage on Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value - PR Newswire

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value  PR Newswire

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value - PR Newswire

Click here to get full coverage on Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation  PR Newswire

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire

Click here to get full coverage on Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PR Newswire

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models  PR Newswire

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PR Newswire

Click here to get full coverage on Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor  PR Newswire

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire

Click here to get full coverage on GLMD’s Unexpected Rise: What’s Fueling the Surge? - StocksToTrade

GLMD’s Unexpected Rise: What’s Fueling the Surge?  StocksToTrade

GLMD’s Unexpected Rise: What’s Fueling the Surge? - StocksToTrade

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Galmed Pharmaceuticals Secures Shareholder Approval at Annual Meeting - TipRanks

Galmed Pharmaceuticals Secures Shareholder Approval at Annual Meeting  TipRanks

Galmed Pharmaceuticals Secures Shareholder Approval at Annual Meeting - TipRanks

Click here to get full coverage on Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - TipRanks

Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position  TipRanks

Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - TipRanks

Click here to get full coverage on Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs - TipRanks

Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs  TipRanks

Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs - TipRanks

Click here to get full coverage on Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy  PR Newswire

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire

Click here to get full coverage on Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks

Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation  TipRanks

Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks

Click here to get full coverage on Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ - Stocktwits

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’  Stocktwits

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ - Stocktwits

Click here to get full coverage on Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025 - TechStock²

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025  TechStock²

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025 - TechStock²

Click here to get full coverage on ​What Is This Super-Powerful Iranian Loitering Munition, Shown at Exhibition in Serbia - Defense Express

​What Is This Super-Powerful Iranian Loitering Munition, Shown at Exhibition in Serbia  Defense Express

​What Is This Super-Powerful Iranian Loitering Munition, Shown at Exhibition in Serbia - Defense Express

Click here to get full coverage on Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology  PR Newswire

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire

Click here to get full coverage on 3 Penny Stocks to Watch Now, 4/29/25 - The Globe and Mail

3 Penny Stocks to Watch Now, 4/29/25  The Globe and Mail

3 Penny Stocks to Watch Now, 4/29/25 - The Globe and Mail

Click here to get full coverage on Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks

Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy  TipRanks

Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks

Click here to get full coverage on Galmed receives patent for combination therapy in South Korea - Investing.com

Galmed receives patent for combination therapy in South Korea  Investing.com

Galmed receives patent for combination therapy in South Korea - Investing.com

Click here to get full coverage on Whittier Daily News - FinancialContent

Whittier Daily News - FinancialContent

Click here to get full coverage on Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat

Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion?  MarketBeat

Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat

Click here to get full coverage on Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - Nasdaq

Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze  Nasdaq

Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - Nasdaq

Click here to get full coverage on GLMD - Galmed Pharmaceu Latest Stock News & Market Updates - Stock Titan

GLMD - Galmed Pharmaceu Latest Stock News & Market Updates  Stock Titan

GLMD - Galmed Pharmaceu Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth? - Yahoo Finance

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?  Yahoo Finance

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth? - Yahoo Finance

Click here to get full coverage on Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com UK

Galmed Phar stock hits 52-week low at $1.75 amid challenges  Investing.com UK

Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com UK

Click here to get full coverage on Galmed Pharmaceuticals forms a Strategic Partnership with OnKai - PR Newswire

Galmed Pharmaceuticals forms a Strategic Partnership with OnKai  PR Newswire

Galmed Pharmaceuticals forms a Strategic Partnership with OnKai - PR Newswire

Click here to get full coverage on Galmed Pharmaceuticals: Surge to $15.10 Raises Caution Amid Overbought Signals and Negative Earnings - StockInvest.us

Galmed Pharmaceuticals: Surge to $15.10 Raises Caution Amid Overbought Signals and Negative Earnings  StockInvest.us

Galmed Pharmaceuticals: Surge to $15.10 Raises Caution Amid Overbought Signals and Negative Earnings - StockInvest.us

Click here to get full coverage on Inchcape adds LDV, SsangYong to Subaru in its NZ operations - Driven Car Guide

Inchcape adds LDV, SsangYong to Subaru in its NZ operations  Driven Car Guide

Inchcape adds LDV, SsangYong to Subaru in its NZ operations - Driven Car Guide

Click here to get full coverage on Galmed Could Double, Even With Reduced Outlook - Barron's

Galmed Could Double, Even With Reduced Outlook  Barron's

Galmed Could Double, Even With Reduced Outlook - Barron's

Click here to get full coverage on Price drops feature in changes to SsangYong lineup - Stuff

Price drops feature in changes to SsangYong lineup  Stuff

Price drops feature in changes to SsangYong lineup - Stuff

Click here to get full coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Crosses Below 50-Day Moving Average – Should You Sell? - Defense World

Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Crosses Below 50-Day Moving Average – Should You Sell?  Defense World

Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Crosses Below 50-Day Moving Average – Should You Sell? - Defense World

Click here to get full coverage on Galmed Pharmaceuticals Ltd. (GLMD) Stock: Soars 10.85% Following Breakthrough Cancer Treatment Results - parameter.io

Galmed Pharmaceuticals Ltd. (GLMD) Stock: Soars 10.85% Following Breakthrough Cancer Treatment Results  parameter.io

GLMD

Price Chart

Key Statistics

Technicals

About GLMD

Latest News

Galmed Issues CEO Letter to Shareholders - PR Newswire

Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement - Stock Titan

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Advanced Charts

Top Gainers

Top Losers